Our findings from deterministic, PSA, and scenario analysis confirm that one-year adjuvant trastuzumab therapy is not cost-effective compared to chemotherapy alone for early-stage breast cancer with HER2+ at its current price of trastuzumab in Vietnam in 2020 from the societal perspective. Here, ERBB2 is linked to breast carcinoma.